PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
0.66%
Revenue growth under 50% of META's 12.29%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
0.69%
Gross profit growth under 50% of META's 12.33%. Michael Burry would be concerned about a severe competitive disadvantage.
-4.94%
Negative EBIT growth while META is at 10.27%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-4.94%
Negative operating income growth while META is at 16.44%. Joel Greenblatt would press for urgent turnaround measures.
-5.88%
Negative net income growth while META stands at 10.17%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-6.67%
Negative EPS growth while META is at 10.47%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-6.67%
Negative diluted EPS growth while META is at 11.04%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.14%
Slight or no buybacks while META is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
-0.04%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
-19.31%
Negative OCF growth while META is at 6.39%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-31.39%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
5879.45%
10Y revenue/share CAGR above 1.5x META's 1223.16%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
318.91%
5Y revenue/share CAGR above 1.5x META's 190.49%. David Dodd would look for consistent product or market expansions fueling outperformance.
71.76%
3Y revenue/share CAGR similar to META's 77.04%. Walter Schloss would assume both companies experience comparable short-term cycles.
No Data
No Data available this quarter, please select a different quarter.
183.87%
Below 50% of META's 653.02%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
65.31%
3Y OCF/share CAGR at 50-75% of META's 125.05%. Martin Whitman would suspect weaker recent execution or product competitiveness.
7396.75%
Net income/share CAGR above 1.5x META's 2770.56% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
356.45%
5Y net income/share CAGR 1.25-1.5x META's 304.58%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
93.95%
Below 50% of META's 194.47%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
No Data
No Data available this quarter, please select a different quarter.
773.52%
5Y equity/share CAGR above 1.5x META's 101.78%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
101.45%
3Y equity/share CAGR above 1.5x META's 66.56%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
17.28%
AR growth well above META's 14.10%. Michael Burry fears inflated revenue or higher default risk in the near future.
-83.46%
Inventory is declining while META stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
12.07%
Asset growth above 1.5x META's 5.19%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
5.93%
Similar to META's 5.80%. Walter Schloss finds parallel capital usage or profit distribution strategies.
No Data
No Data available this quarter, please select a different quarter.
9.78%
R&D growth drastically higher vs. META's 6.52%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
7.18%
SG&A growth well above META's 12.01%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.